ALNY
Alnylam Pharmaceuticals Inc
NASDAQ: ALNY · HEALTHCARE · BIOTECHNOLOGY
$284.84
-0.19% today
Updated 2026-06-05
Market cap
$37.76B
P/E ratio
70.89
P/S ratio
8.81x
EPS (TTM)
$3.99
Dividend yield
—
52W range
$282 – $496
Volume
1.1M
WallStSmart proprietary scores
65
out of 100
Grade: B
Buy
Investment rating
8.0
Growth
A5.5
Quality
C+8.0
Profitability
A7.3
Valuation
B+4/9
Piotroski F-Score
Moderate
-0.1
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$446.81
+56.86%
12-Month target
$15.91
-94.41%
Intrinsic (DCF)
$2,372.19
Margin of safety
+86.41%
7 Strong Buy15 Buy8 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ ROE 53.68% — strong efficiency
+ Free cash flow $48.67M — positive
+ Revenue growth 96.40% QoQ
+ 86.41% below intrinsic value
Risks
- Altman Z -0.07 — distress zone
- P/E 70.89x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $1.04B | $1.83B | $2.25B | $3.71B | $4.29B | $5.7B |
| Net income | $-1.13B | $-440.24M | $-278.16M | $313.75M | $205.99M | — |
| EPS | — | — | — | — | $3.99 | $7.37 |
| Free cash flow | $-613.33M | $41.95M | $-42.59M | $465.38M | $48.67M | — |
| Profit margin | -109.04% | -24.08% | -12.37% | 8.45% | 12.60% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-01 | PYOTT, DAVID E I | Sale | 3,830 | — |
| 2026-06-01 | PYOTT, DAVID E I | Buy | 3,830 | — |
| 2026-06-01 | PYOTT, DAVID E I | Sale | 1,222 | $299.87 |
Peer comparison
Smart narrative
Alnylam Pharmaceuticals Inc trades at $284.84. representing a P/E of 70.89x trailing earnings. Our Smart Value Score of 65/100 indicates the stock is good. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -0.07, it sits in the distress. TTM revenue stands at $4.29B. with profit margins at 12.60%. Our DCF model estimates intrinsic value at $2,372.19.
Frequently asked questions
What is Alnylam Pharmaceuticals Inc's stock price?
Alnylam Pharmaceuticals Inc (ALNY) trades at $284.84, on a P/E of 70.9x and a P/S of 8.8x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Alnylam Pharmaceuticals Inc overvalued?
Alnylam Pharmaceuticals Inc carries a Smart Value Score of 65/100 (Grade B), which we rate Buy. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $2,372.19 versus the $284.84 price, a 86.4% margin of safety on a cash flow basis.
What is the price target of Alnylam Pharmaceuticals Inc (ALNY)?
The 12-month analyst consensus target is $446.81, about 56.9% above the current $284.84. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of ALNY by 2030?
Our research-backed model puts the 2030 base case at $413.45, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of Alnylam Pharmaceuticals Inc (ALNY)?
Our DCF model estimates intrinsic value at $2,372.19, a +86.4% margin of safety versus today's $284.84. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Alnylam Pharmaceuticals Inc's revenue?
Alnylam Pharmaceuticals Inc's trailing twelve-month revenue is $4.29B, and our model projects it reaching about $13.92B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Alnylam Pharmaceuticals Inc's Altman Z-Score is -0.07, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio8.81x
ROE53.68%
Beta0.27
50D MA$303.86
200D MA$377.74
Shares out0.13B
Float0.13B
Short ratio—
Avg volume1.1M
Performance
1 week+0.00%
1 month+5.60%
3 months-3.31%
YTD-23.79%
1 year—
3 years—
5 years—